🇺🇸 IPI-145 in United States
36 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 36
Most-reported reactions
- Enteritis Infectious — 6 reports (16.67%)
- Dehydration — 5 reports (13.89%)
- Diarrhoea — 5 reports (13.89%)
- Stomatitis — 4 reports (11.11%)
- Dyspnoea — 3 reports (8.33%)
- Gastritis — 3 reports (8.33%)
- Sepsis — 3 reports (8.33%)
- Vomiting — 3 reports (8.33%)
- Abdominal Pain — 2 reports (5.56%)
- Cardiac Failure — 2 reports (5.56%)
Other Oncology approved in United States
Frequently asked questions
Is IPI-145 approved in United States?
IPI-145 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for IPI-145 in United States?
SecuraBio is the originator. The local marketing authorisation holder may differ — check the official source linked above.